Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SPRY

ARS Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SPRY. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.17

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 17:52 UTC.

What ARS Pharmaceuticals, Inc. does

ARS Pharmaceuticals is a biopharmaceutical company that commercializes and develops neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. neffy uses an innovative absorption enhancer called Intravail and is the first and only FDA and European Commission-approved needle-free epinephrine product, with approvals also in the U.K., Japan, Australia, and China. The company has launched neffy in the U.S.

Summarized from ARS Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.17
Debt/equity7.73

Revenue, margins & earnings

FY2021: net loss $20M on revenue $6M$6MFY2021FY2022: net loss $35M on revenue $1M$1MFY2022FY2023: net loss $54M on revenue $30,000$30,000FY2023FY2024 Revenue: $89M — margin split not shown (non-operating gains)$89MFY2024FY2025: net loss $171M on revenue $84M$84MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-05
  • 2026-10-05President and CEOStock Option (right to buy)Award1,036,923—
  • 2026-09-02Chief Commercial OfficerStock Option (right to buy)Award1,001,738—
  • 2026-07-02PresidentStock Option (right to buy)Award898,456—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does ARS Pharmaceuticals, Inc. do?

ARS Pharmaceuticals is a biopharmaceutical company that commercializes and develops neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis.

When did SPRY last file with the SEC?

ARS Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 17:52 UTC. This page is also available as JSON at /api/data?ticker=SPRY and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SPRY and 5,000+ tickers.

Create a free account — keep SPRY
For your agent
GET /api/data?ticker=SPRY

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt